Results 21 to 30 of about 390,088 (309)

Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group

Clinical Ophthalmology, 2018
Winfried Amoaku,1 Konstantinos Balaskas,2,3 Tomas Cudrnak,4 Louise Downey,5 Markus Groppe,6 Sajjad Mahmood,7 Hemal Mehta,8 Quresh Mohamed,9 Bushra Mushtaq,10 Philip Severn,11 Athanasios Vardarinos,12 Yit Yang,13 Saad Younis14 1Academic Ophthalmology ...
Amoaku W, Balaskas K, Cudrnak T, Downey L, Groppe M, Mahmood S, Mehta H, Mohamed Q, Mushtaq B, Severn P, Vardarinos A, Yang Y, Younis S   +12 more
doaj   +1 more source

OCT biomarkers as predictors of treatment interval in neovascular age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen [PDF]

Scientific Reports
Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss in older adults. Treat-and-extend (T&E) regimen for anti-vascular endothelial growth factor therapy are widely used to individualize treatment, yet substantial ...
Jae Hyup Lee, Sang-Yoon Lee, Boa Jang, Young-Gon Kim, Chang Ki Yoon, Un Chul Park, Kyu Hyung Park, Eun Kyoung Lee   +7 more
doaj   +2 more sources

Real-Life Evidence for Using a Treat-and-Extend Injection Regime for Patients with Central Retinal Vein Occlusion

Ophthalmology and Therapy, 2019
Introduction To report the 52-week treatment outcomes with intravitreal injections of aflibercept using a treat-and-extend regimen for treating macular edema secondary to central retinal vein occlusion (CRVO). Methods A retrospective analysis of patients
Maria Eleftheriadou, Luke Nicholson, Giulia D’Alonzo, Peter K. F. Addison   +3 more
doaj   +2 more sources

Real-World Outcomes of Aflibercept 2 mg Using a Treat-and-Extend Protocol for Neovascular Age-Related Macular Degeneration: A 24-Month Retrospective Study in a Chinese Population [PDF]

Drug Design, Development and Therapy
Yuanyuan Qi,* Aixuan Cheng,* Jiayang Xu, Chao Zhang, Sheng Li Department of Ophthalmology, Dalian Third People’s Hospital Affiliated to Dalian University of Technology, Dalian, People’s Republic of China*These authors contributed ...
Qi Y, Cheng A, Xu J, Zhang C, Li S
doaj   +2 more sources

TREAT-AND-EXTEND BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Retina, 2014
To evaluate the factors affecting visual and anatomical outcomes and the number of intravitreal bevacizumab injections required in the treatment of neovascular age-related macular degeneration using a treat-and-extend regimen.Retrospective consecutive case series.
Rush, R, Simunovic, M, Vandiver, L, Aragon, A, Ysasaga, J   +4 more
openaire   +3 more sources

Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study

Graefe's Archive for Clinical and Experimental Ophthalmology, 2019
To compare treatment efficacy of anti-VEGF medications following pro re nata (PRN, “as needed”, monthly injections only in case of active disease) or treat and extend (T&E, progressive extension of treatment intervals up to 12 weeks depending on the ...
Pascal Imesch
exaly   +2 more sources

Efficacy and safety of treat-and-extend intravitreal brolucizumab in naive and switched patients with macular neovascularization: one-year follow-up study [PDF]

BMC Ophthalmology
Background to analyze, at one year, the efficacy and safety of treat-and-extend (T&E) intravitreal (IV) Brolucizumab in patients affected by macular neovascularization (MNV).
Francesco Faraldi, Carlo Alessandro Lavia, Marco Nassisi, Raphael Kilian, Clara Rizzo, Maria Cristina Savastano, Stanislao Rizzo, Fabrizio Giansanti, Daniela Bacherini   +8 more
doaj   +2 more sources

Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial [PDF]

JAMA ophthalmology, 2019
Importance To our knowledge, this is the first randomized clinical trial to compare visual outcomes and injection loads between ranibizumab and aflibercept using an identical treat-and-extend (TE) regimen for neovascular age-related macular degeneration (
M. Gillies, A. Hunyor, J. Arnold, R. Guymer, S. Wolf, P. Ng, F. Pecheur, I. McAllister   +7 more
semanticscholar   +2 more sources

Recurrence of neovascular age-related macular degeneration after discontinuation of modified treat and extend treatment [PDF]

Scientific Reports
We evaluated the incidence and risk factors for recurrence in patients with neovascular age-related macular degeneration (nAMD) who discontinued anti-vascular endothelial growth factor (VEGF) therapy under a modified treat-and-extend (TAE) protocol.
Junwoo Lee, Jaehwan Choi, Seung-Young Yu, Kiyoung Kim   +3 more
doaj   +2 more sources

Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study. [PDF]

Ophthalmology (Rochester, Minn.), 2018
PURPOSE To evaluate the efficacy and safety of ranibizumab 0.5 mg treat-and-extend (T&E) versus monthly regimens in patients with neovascular age-related macular degeneration (nAMD) from the TReat and extEND (TREND) study.
Rufino Silva, A. Berta, M. Larsen, W. Macfadden, C. Feller, J. Monés   +5 more
semanticscholar   +2 more sources